Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.

Glass LC, Qu Y, Lenox S, Kim D, Gates JR, Brodows R, Trautmann M, Bergenstal RM

Current medical research and opinion23 Jan 2008Cited by 23 (Europe PMC)

PMID18218179DOI10.1185/030079908x260862PepBankPUB-18218179

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide and insulin analogue therapy provided similarly effective glycemic control.
In plain wordsIn people with type 2 diabetes, exenatide controlled blood sugar similarly to insulin analogue therapy.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlycemic control
Study
n = 1,047
Comparator
Insulin analogue therapy (glargine or biphasic insulin aspart)
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mug twice daily for 4 weeks, 10 mug thereafter · 6 monthsAs given in this study (human).
Source sentences
Summary
While exenatide treatment provided similarly effective glycemic control compared with insulin analogue therapy
1 context sentence(design, population, supporting numbers)
Summary · context
In this pooled post-hoc analysis of two trials, 1047 subjects with diabetes were compared regarding the relative impact of an adjunctive treatment - an insulin analogue (glargine or biphasic insulin aspart) or exenatide (5 mug twice daily for 4 weeks, 10 mug thereafter) - on body weight.
Report a problemFND-1821817901
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide was associated with mean weight loss, whereas insulin therapy produced weight gain.
In plain wordsIn people with diabetes, exenatide was linked to weight loss compared with weight gain during insulin therapy.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMean weight change
Study
n = 1,047
Comparator
Insulin analogue therapy (glargine or biphasic insulin aspart)
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mug twice daily for 4 weeks, 10 mug thereafter · 6 monthsAs given in this study (human).
Measurements
Mean weight decrease
3 kg
exenatide
Mean weight gain
3 kg
insulin analogue
Source sentences
Summary
it was also associated with weight reduction in the majority of subjects (73.3%, averaging 3 kg decrease by endpoint)
2 context sentences(design, population, supporting numbers)
Summary · context
In contrast, by the end of the study most insulin-treated subjects (75.9%) had gained weight (mean 3 kg).
Summary · context
In this pooled post-hoc analysis of two trials, 1047 subjects with diabetes were compared regarding the relative impact of an adjunctive treatment - an insulin analogue (glargine or biphasic insulin aspart) or exenatide (5 mug twice daily for 4 weeks, 10 mug thereafter) - on body weight.
Report a problemFND-1821817902
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, approximately 22% receiving exenatide achieved at least 5% weight loss versus 2% with insulin.
In plain wordsIn people with diabetes, more participants lost at least 5% of their weight with exenatide than with insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight loss at least 5%
Study
n = 1,047
Comparator
Insulin analogue therapy (glargine or biphasic insulin aspart)
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mug twice daily for 4 weeks, 10 mug thereafter · 6 monthsAs given in this study (human).
Measurements
Responder proportion
≈ 22%
exenatide
Responder proportion
2%
insulin
Source sentences
Summary
with approximately 22% achieving > or =5% weight loss,
2 context sentences(design, population, supporting numbers)
Summary · context
Only 2% of insulin-treated subjects achieved > or =5% weight loss, and 0.2% of subjects achieved > or =10% weight loss.
Summary · context
In this pooled post-hoc analysis of two trials, 1047 subjects with diabetes were compared regarding the relative impact of an adjunctive treatment - an insulin analogue (glargine or biphasic insulin aspart) or exenatide (5 mug twice daily for 4 weeks, 10 mug thereafter) - on body weight.
Report a problemFND-1821817904
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, 3.2% receiving exenatide achieved at least 10% weight loss versus 0.2% with insulin.
In plain wordsIn people with diabetes, more participants lost at least 10% of their weight with exenatide than with insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight loss at least 10%
Study
n = 1,047
Comparator
Insulin analogue therapy (glargine or biphasic insulin aspart)
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mug twice daily for 4 weeks, 10 mug thereafter · 6 monthsAs given in this study (human).
Measurements
Responder proportion
3.2%
exenatide
Responder proportion
0.2%
insulin
Source sentences
Summary
and 3.2% of subjects achieving > or =10% weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
Only 2% of insulin-treated subjects achieved > or =5% weight loss, and 0.2% of subjects achieved > or =10% weight loss.
Summary · context
In this pooled post-hoc analysis of two trials, 1047 subjects with diabetes were compared regarding the relative impact of an adjunctive treatment - an insulin analogue (glargine or biphasic insulin aspart) or exenatide (5 mug twice daily for 4 weeks, 10 mug thereafter) - on body weight.
Report a problemFND-1821817905
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, 73.3% of exenatide-treated subjects lost weight.
In plain wordsIn people with type 2 diabetes, most exenatide-treated participants lost weight.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableAny weight reduction
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mug twice daily for 4 weeks, 10 mug thereafter · 6 monthsAs given in this study (human).
Measurements
Weight reduction
73.3%
exenatide
Source sentences
Summary
it was also associated with weight reduction in the majority of subjects (73.3%, averaging 3 kg decrease by endpoint)
1 context sentence(design, population, supporting numbers)
Summary · context
In this pooled post-hoc analysis of two trials, 1047 subjects with diabetes were compared regarding the relative impact of an adjunctive treatment - an insulin analogue (glargine or biphasic insulin aspart) or exenatide (5 mug twice daily for 4 weeks, 10 mug thereafter) - on body weight.
Report a problemFND-1821817903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.